Market revenue in 2023 | USD 254.7 million |
Market revenue in 2030 | USD 344.2 million |
Growth rate | 4.4% (CAGR from 2023 to 2030) |
Largest segment | Pcr-based diagnostics |
Fastest growing segment | NGS DNA Diagnosis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | PCR-based Diagnostics, NGS DNA Diagnosis, In-Situ Hybridization Diagnostics, Microarrays-based Diagnostics |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories Inc, Thermo Fisher Scientific Inc, Illumina Inc, Danaher Corp, Hologic Inc, Siemens Healthineers AG ADR, Roche, Qiagen NV, Agilent Technologies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dna diagnostics market will help companies and investors design strategic landscapes.
Pcr-based diagnostics was the largest segment with a revenue share of 49.78% in 2023. Horizon Databook has segmented the UK dna diagnostics market based on pcr-based diagnostics, ngs dna diagnosis, in-situ hybridization diagnostics, microarrays-based diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of sophisticated healthcare infrastructure, collaborations between key players, and an increasing number of novel product launches are anticipated to contribute to market growth in the UK. Moreover, government support & initiatives are expected to propel the DNA diagnostics market in the coming decade.
According to an article published by HEE Genomics Education Programme in March 2023, the UK National Screening Committee (UK NSC) recently suggested that all newborn blood spot testing programs in England, Scotland, Wales, and Northern Ireland include a genetic disorder known as tyrosinaemia type 1. Moreover, across the nation, newborn blood spot screening may soon include the rare illness tyrosinaemia type 1. Such programs are anticipated to contribute to future market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the UK dna diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into UK dna diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account